The final programme of the event ““Liquid biopsy, nanotechnology and photonics for precision“, closing event of the ULTRAPLACAD project” is available!
During the event, held in Rome on 25^th October, you will have the opportunity to meet EU and International representatives from research and industry, clinicians, public authorities, and stakeholders and listen presentations about innovative tools for cancer molecular diagnosis through liquid biopsy.

At the exhibition area, the participants will have the opportunity to interact with EU companies showing the most advanced technologies in the field of plasmonics, microfluidics, large-scale production of integrated chips and assay development for nucleic acids and protein detection.

Colorectal cancer (CRC) as compared to breast, lung, and prostate cancers, represents more than 50% of cancer incidence in Europe. An early detection of cancer has been shown to reduce the mortality from colorectal cancer. The plasmonic devices developed in ULTRAPLACAD will allow a non-invasive early diagnosis of the disease. To better understand the needs of patients and procedures for diagnosis, prognosis and therapy efficacy assessment, the ULTRAPLACAD project is supporting the initiatives of EuropaColon association, including the survey on the unmet needs for patients living with metastatic CRC. You can participate to the survey at the following link: http://www.europacolon.com/survey.php?Action=Survey ​​​​​​​

Biomarker detection is a key aspect to new minimally-invasive diagnostic approaches. ULTRAPLACAD project aims at the development of a novel in vitro diagnostic system for early cancer diagnosis based on molecular analysis of peripheral blood (liquid biopsy). This approach is supported by the ULTRAPLACAD partners Regina Elena National Cancer Institute and University of Ferrara, as explained by Prof. Giacomini in this video. Enjoy it!